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Expanded Abstract 
Citation 
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Mockel J, Vincent JL: Relative adrenal insufficiency in 
patients with septic shock: comparison of low-dose and 
conventional corticotropin tests. Crit Care Med 2005, 
33:2479-2486 [1]. 
Objective 
To compare a low-dose (1 µg) adrenocorticotropic hormone 
(ACTH) stimulation test with the more standard (250 µg) 
test for the diagnosis of relative adrenal insufficiency. 
Methods 
Design and setting: Diagnostic study in a thirty-one bed 
mixed medico-surgical department of intensive care 
Patients: Forty-six consecutive patients with septic shock. 
Intervention: Corticotropin stimulation tests (low-dose test, 
1 µg, and standard 250-µg test), performed consecutively at 
an interval >4 hrs. 
Measurements and main results: In each test, serum 
cortisol levels were measured before (T0) and 30 (T30), 60 
(T60), and 90 (T90) mins after corticotropin injection. The 
maximal increase in cortisol (∆max) was calculated as the 
difference between T0 and the highest cortisol value at T30, 
T60, or T90 and considered as adequate if >9 µg/dL (250 
nmol/L). Nonresponders to the low dose test had a lower 
survival rate than responders to both tests (27 vs. 47%, p = 
.06; Kaplan Meier curves). Interestingly, nonresponders to 
high-dose test received hydrocortisone treatment and had a 
similar survival to responders. Multivariable logistic 
regression disclosed that the response to the combined low-
dose test and high-dose test was an independent predictor 
of survival (odds ratio 28.91, 95% confidence interval 1.81–
462.70, p = .017), whereas basal or maximal cortisol levels 
in both tests were not. 
Conclusion 
The low-dose test identified a subgroup of patients in septic 
shock with inadequate adrenal reserve who had a worse 
outcome and would have been missed by the high-dose 
test. These patients may also benefit from glucocorticoid 
replacement therapy. 
Commentary 
A variety of methods have been used to detect adrenal 
insufficiency in patients with septic shock, including the 250 
µg ACTH stimulation test (standard or “high- dose” test), the 
1 µg ACTH stimulation test (“low-dose” test), measurement 
of random cortisol levels, measurement of free cortisol 
levels, and determination of the hemodynamic response to 
hydrocortisone. However, only the high-dose ACTH test 
was shown to detect patients who are likely to receive a 
mortality benefit from corticosteroid (steroid) replacement 
therapy [2]. Based on these findings, corticosteroid 
replacement has become the standard of care for septic 
shock patients who fail to demonstrate an in increase 
plasma cortisol level by 9 µg/dL or more after injection of 
250  µg of ACTH. Recently, a subgroup of septic shock 
patients was identified that responded adequately to the 
high-dose ACTH test, yet inadequately to the low-dose test 
[3]. The impact of this finding on outcome is unclear, since 
all patients in the study received replacement doses of 
corticosteroids. 
In the current study, Siraux and colleagues found that as 
many as 50% of high-dose responders failed to respond to 
the low-dose test and that this discordant subset of patients 
showed a trend toward worse 28-day mortality. The authors 
speculated that the low-dose test might identify an 
additional group of septic shock patients who can benefit 
from therapy with corticosteroids. 
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Strengths of this study include the use of standard 
definitions for septic shock and infection as well as invasive 
monitoring with goal directed therapy. Patients were 
excluded if they received steroids in the month prior or if 
they were given etomidate <24 hours before the ACTH test. 
This latter exclusion was critical, since etomidate seems to 
cause significant but transient adrenocortical suppression 
especially during the first 24 hours after administration [4], 
though the duration of adrenal suppression induced by 
etomidate is controversial [5]. Exclusion of these patients 
may explain the lower prevalence of relative adrenal 
insufficiency in this study as compared to others [2,6], 
although other factors, such differences in illness severity 
and the type of cortisol assay used, also may have played a 
role. 
Because the subset of patients with discordant results did 
not receive replacement steroids, the clinician is left with a 
bit of a conundrum. On one hand, we may be missing 
patients with septic shock who can benefit from steroid 
replacement; on the other hand, steroids can cause 
important side effects, such as increased risk of infection or 
impair wound healing. Furthermore, there is no evidence of 
that administering corticosteroid improves outcome for 
patients, who fail to respond to the low-dose ACTH test. 
Recommendation 
The current evidence showing improved mortality with 
steroid replacement is limited to patients with septic shock 
who are nonresponders to the high-dose ACTH test. It 
remains to be seen whether the subgroup of nonresponders 
identified by the low-dose test also will benefit from 
treatment with replacement doses of corticosteroids. Until 
such data are available, we recommend that only 
nonresponders to the high-dose test receive replacement 
steroids.  
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